Using a worldwide in-app survey to explore sugammadex usage patterns: a prospective observational study

Editor—Via encapsulation, sugammadex can rapidly and completely reverse even profound neuromuscular block induced by rocuronium or vecuronium, which is not possible to achieve with cholinesterase inhibitors.^1–4 Although approved for use in Europe in 2008⁵ and available for several years elsewhere,⁶ the United States Food and Drug Administration (US FDA) delayed approval due to concerns regarding potential hypersensitivity reactions and effects on coagulation tests,⁷ which were ultimately satisfied.^8–10 We are interested in better understanding global experience with sugammadex and the impact, if any, of pharmacoeconomics on post-marketing policies. The present data were analysed from an ongoing, Institutional Review Board (IRB)-approved (Emory University, Atlanta, GA, USA, IRB# 00082571) study of a globally utilized anaesthesia calculator app for the Android platform ('Anesthesiologist')¹¹¹² fitted with a module capable of collecting survey data and app analytics.¹³ We used this tool to deploy a survey assessing global patterns of clinical practice and experience with sugammadex.

http://ift.tt/2eRSfNJ